Vir Biotechnology Inc. [NASDAQ: VIR] gained 0.39% or 0.11 points to close at $28.68 with a heavy trading volume of 2967919 shares. The company report on September 8, 2020 that Vir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment Conference.
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will virtually present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16 at 11:00 am PT / 2:00 pm ET.
A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.
It opened the trading session at $28.28, the shares rose to $31.46 and dropped to $27.88, the range by which the price of stock traded the whole day. The daily chart for VIR points out that the company has recorded -4.11% loss over the past six months. However, it is still -146.18% lower than its most recent low trading price.
If we look at the average trading volume of 1.28M shares, VIR reached to a volume of 2967919 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Vir Biotechnology Inc. [VIR]:
Needham have made an estimate for Vir Biotechnology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 20, 2020. The new note on the price target was released on March 19, 2020, representing the official price target for Vir Biotechnology Inc. stock.
The Average True Range (ATR) for Vir Biotechnology Inc. is set at 3.56, with the Price to Sales ratio for VIR stock in the period of the last 12 months amounting to 52.70. The Price to Book ratio for the last quarter was 5.85, with the Price to Cash per share for the same quarter was set at 4.00.
Trading performance analysis for VIR stock
Vir Biotechnology Inc. [VIR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.15. With this latest performance, VIR shares dropped by -44.88% in over the last four-week period, additionally sinking by -4.11% over the last 6 months .
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VIR stock in for the last two-week period is set at 19.30, with the RSI for the last a single of trading hit 14.15, and the three-weeks RSI is set at 27.81 for Vir Biotechnology Inc. [VIR]. The present Moving Average for the last 50 days of trading for this stock 46.22, while it was recorded at 31.11 for the last single week of trading, and 31.78 for the last 200 days.
Vir Biotechnology Inc. [VIR]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Vir Biotechnology Inc. [VIR] shares currently have an operating margin of -2144.35. Vir Biotechnology Inc.’s Net Margin is presently recorded at -2158.98.
Return on Total Capital for VIR is now -62.52, given the latest momentum, and Return on Invested Capital for the company is -62.97. Return on Equity for this stock declined to -63.07, with Return on Assets sitting at -49.65. When it comes to the capital structure of this company, Vir Biotechnology Inc. [VIR] has a Total Debt to Total Equity ratio set at 0.27. Additionally, VIR Total Debt to Total Capital is recorded at 0.27, with Total Debt to Total Assets ending up at 0.22. Long-Term Debt to Equity for the company is recorded at 0.21, with the Long-Term Debt to Total Capital now at 0.21.
Reflecting on the efficiency of the workforce at the company, Vir Biotechnology Inc. [VIR] managed to generate an average of -$762,808 per employee.Vir Biotechnology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.50 and a Current Ratio set at 10.50.
Vir Biotechnology Inc. [VIR]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Vir Biotechnology Inc. posted -4.6/share EPS, while the average EPS was predicted by analysts to be reported at -3.71/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -24.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VIR.
An analysis of insider ownership at Vir Biotechnology Inc. [VIR]
There are presently around $1,513 million, or 44.90% of VIR stock, in the hands of institutional investors. The top three institutional holders of VIR stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 22,616,666, which is approximately 0% of the company’s market cap and around 4.10% of the total institutional ownership; TEMASEK HOLDINGS (PRIVATE) LTD, holding 5,499,999 shares of the stock with an approximate value of $157.74 million in VIR stocks shares; and ALASKA PERMANENT FUND CORP, currently with $137.66 million in VIR stock with ownership of nearly 220% of the company’s market capitalization.
Positions in Vir Biotechnology Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 99 institutional holders increased their position in Vir Biotechnology Inc. [NASDAQ:VIR] by around 18,261,772 shares. Additionally, 14 investors decreased positions by around 1,688,858 shares, while 7 investors held positions by with 32,803,766 shares. The mentioned changes placed institutional holdings at 52,754,396 shares, according to the latest SEC report filing. VIR stock had 62 new institutional investments in for a total of 3,780,789 shares, while 10 institutional investors sold positions of 599,720 shares during the same period.